RVMD ▼ -1.5% - Revolution Medicines, Inc. $RVMD - Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer Revolution Medicines' stock declined 1.5% despite receiving U.S. FDA Breakthrough Therapy Designation for RASONQUE in combination with chemotherapy for first-line metastatic pancreatic cancer. The designation, which typically signals potential accelerated development and review pathways, was apparently insufficient to drive positive momentum in today's trading. 14-SEP-2026 04:05 PM ET